NeoGenomics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
NeoGenomics, Inc. (NEO) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $4.93 million as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-17
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.93M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.86M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.62M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.80M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $4.93M 10-K · filed 2026-02-17 |
| 2024-12-31 | $3.86M 10-K · filed 2026-02-17 |
| 2023-12-31 | $2.62M 10-K · filed 2025-02-18 |
| 2022-12-31 | $2.80M 10-K · filed 2024-02-20 |
| 2021-12-31 | $2.35M 10-K · filed 2023-02-24 |
| 2020-12-31 | $2.00M 10-K · filed 2022-02-25 |
| 2019-12-31 | $2.06M 10-K · filed 2021-02-25 |
| 2018-12-31 | $1.61M 10-K · filed 2020-02-28 |
| 2017-12-31 | $1.34M 10-K · filed 2019-02-26 |
| 2016-12-31 | $1.26M 10-K · filed 2018-03-13 |
| 2015-12-31 | $1.38M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |